Payment overview · 2025
General Payments
$249.98
2 reported records · 2 companies
Healthcare provider profile · identity verified
Peter Emil Crosson
Allopathic & Osteopathic Physicians|Internal Medicine · HYANNIS, MA · NPI 1952481095
Verified facts
What the public records show
CMS Open Payments records show Peter Emil Crosson received $249.98 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.99 | 50.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.99 | 50.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $249.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 121 |
| Omeprazole | Omeprazole | 443 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 101 |
| Lorazepam | Lorazepam | 327 | 74 |
| Lisinopril | Lisinopril | 292 | 83 |
| Gabapentin | Gabapentin | 288 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 265 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 71 |
| Losartan Potassium | Losartan Potassium | 248 | 62 |
| Trazodone Hcl | Trazodone Hcl | 238 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 63 |
| Eliquis | Apixaban | 210 | 44 |
| Simvastatin | Simvastatin | 210 | 57 |
| Meloxicam | Meloxicam | 206 | 53 |
| Tramadol Hcl | Tramadol Hcl | 200 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 53 |
| Atenolol | Atenolol | 164 | 49 |
| Prednisone | Prednisone | 154 | 92 |
| Jardiance | Empagliflozin | 142 | 28 |
| Finasteride | Finasteride | 130 | 38 |
| Allopurinol | Allopurinol | 127 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 31 |
| Furosemide | Furosemide | 111 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 28 |
| Alprazolam | Alprazolam | 105 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 40 |
| Sertraline Hcl | Sertraline Hcl | 101 | 27 |
| Metformin Hcl | Metformin Hcl | 93 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Januvia | Sitagliptin Phosphate | 75 | 16 |
| Azithromycin | Azithromycin | 71 | 58 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | 23 |
| Mirtazapine | Mirtazapine | 62 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 61 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 55 | 14 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Glimepiride | Glimepiride | 52 | 14 |
| Carvedilol | Carvedilol | 50 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 31 |
| Ozempic | Semaglutide | 46 | suppressed |
| Valsartan | Valsartan | 46 | 12 |
| Diazepam | Diazepam | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Torsemide | Torsemide | 42 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 34 | 16 |
| Famotidine | Famotidine | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 17 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 12 |
| Myrbetriq | Mirabegron | 27 | 11 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Testosterone | Testosterone | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Risperidone | Risperidone | 24 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trospium Chloride | Trospium Chloride | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Viberzi | Eluxadoline | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $249.98 · 2 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error